exocrine pancreatic insufficiency
Information
- Disease name
- exocrine pancreatic insufficiency
- Disease ID
- DOID:13316
- Description
- "A pancreas disease that is characterized by the inability of the exocrine pancreas to produce and secrete an adequate amount of digestive enzymes into the small intestine." [url:https\://www.ncbi.nlm.nih.gov/books/NBK555926/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06278272 | Completed | AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients | March 1, 2023 | January 1, 2024 | |
| NCT00408317 | Completed | Phase 3 | Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) | November 2006 | April 2007 |
| NCT00449878 | Completed | Phase 3 | Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency | May 2007 | June 2008 |
| NCT00449904 | Completed | Phase 3 | Open-Label Phase III Long-Term Safety Trial of Liprotamase | June 2007 | April 2009 |
| NCT01430234 | Completed | Phase 4 | Enzyme Suppletion in Exocrine Pancreatic Dysfunction | October 2011 | February 2013 |
| NCT02279498 | Completed | Phase 3 | SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis | June 2015 | January 20, 2017 |
| NCT02370537 | Completed | Phase 2 | A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI | March 2015 | November 2015 |
| NCT02563080 | Completed | Pancreatic Exocrine Insufficiency in Acute Pancreatitis | September 2015 | February 2022 | |
| NCT02598128 | Completed | N/A | Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) | November 2015 | June 2016 |
| NCT02734810 | Completed | Phase 3 | SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis | June 2016 | March 2017 |
| NCT02823964 | Completed | Phase 4 | EASY: Extended Access to Sollpura Over Years | September 2016 | March 2018 |
| NCT03236038 | Completed | Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis | October 1, 2017 | December 31, 2019 | |
| NCT03407534 | Completed | Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating | November 2015 | February 15, 2022 | |
| NCT04966897 | Completed | N/A | Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis | August 31, 2018 | September 30, 2019 |
| NCT05082051 | Completed | Phase 1 | Oral CDX-7108 in Healthy Adults and EPI Subjects | October 11, 2021 | March 16, 2023 |
| NCT05385211 | Completed | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes | April 30, 2022 | August 30, 2023 | |
| NCT05719311 | Completed | Phase 2 | Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis | February 1, 2023 | July 28, 2023 |
| NCT00297167 | Completed | Phase 3 | Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency | May 2006 | November 2006 |
| NCT00559052 | Completed | Phase 2 | An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) | March 2008 | February 2009 |
| NCT00559364 | Completed | Phase 3 | Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea | November 2007 | July 2009 |
| NCT00662675 | Completed | Phase 3 | A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency | August 2008 | February 2009 |
| NCT00676702 | Completed | Phase 1 | A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI) | July 2008 | January 2009 |
| NCT00743483 | Completed | Phase 2 | Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency | August 2008 | June 2009 |
| NCT00788593 | Completed | Phase 3 | A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI) | January 2008 | March 2009 |
| NCT00981214 | Completed | Phase 3 | Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency | May 2006 | September 2006 |
| NCT01100606 | Completed | Phase 4 | A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age | June 2010 | December 2010 |
| NCT01131507 | Completed | Phase 4 | PR-018: An Open-Label, Safety Extension of Study PR-011 | July 2010 | December 2011 |
| NCT01327703 | Completed | Phase 4 | Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency | April 2011 | May 2012 |
| NCT01424696 | Completed | Baby Observational and Nutritional Study | December 2011 | April 2015 | |
| NCT01427712 | Completed | Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis | August 2011 | March 2018 | |
| NCT01427725 | Completed | Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency | September 2011 | April 2015 | |
| NCT05112328 | Recruiting | N/A | The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding | July 7, 2021 | July 31, 2026 |
| NCT05480241 | Recruiting | N/A | Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy | May 1, 2022 | December 31, 2024 |
| NCT04548778 | Recruiting | BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency | November 1, 2020 | December 2023 | |
| NCT05450627 | Recruiting | Registry of Pancreatic Exocrine Insufficiency. | June 1, 2021 | December 31, 2023 | |
| NCT04690738 | Recruiting | Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation | August 17, 2020 | December 31, 2030 | |
| NCT06052293 | Recruiting | Phase 1 | Phase 1 Study to Assess Safety and Efficacy of ANG003 | August 25, 2023 | June 24, 2024 |
| NCT02175459 | Recruiting | Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy | August 2010 | December 2024 | |
| NCT00744250 | Terminated | Phase 4 | Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control | August 2008 | May 2010 |
| NCT00500084 | Terminated | Phase 3 | Phase III ALTU-135 CP Safety Trial | December 2007 | March 2009 |
| NCT00749099 | Terminated | N/A | Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) | April 2007 | September 2010 |
| NCT04112836 | Unknown status | Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer | March 15, 2019 | August 2020 | |
| NCT05261997 | Unknown status | N/A | Endotherapy for Painless Chronic Pancreatitis | March 2022 | November 2023 |
| NCT03051490 | Unknown status | Phase 3 | RESULT: Reliable, Emergent Solution Using Liprotamase Treatment | April 28, 2017 | June 2018 |
| NCT00663975 | Withdrawn | N/A | Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients | February 2009 | November 2009 |
- Disase is a (Disease Ontology)
- DOID:26
- Cross Reference ID (Disease Ontology)
- ICD10CM:K86.81
- Cross Reference ID (Disease Ontology)
- MESH:D010188
- Cross Reference ID (Disease Ontology)
- NCI:C84316
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:47367009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0267963
- Exact Synonym (Disease Ontology)
- EPI
- HPO alt_id (Human Phenotype Ontology)
- HP:0002581
- HPO alt_id (Human Phenotype Ontology)
- HP:0004508
- HPO alt_id (Human Phenotype Ontology)
- HP:0004509
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0001738
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010188